Whitney Faas, NP
Family · Scottsdale, AZNPI 1215432208
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.5%), education and consulting fees — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Astellas Pharma US Inc at 28.6% of the total.
Across 12 payments — averaging $41.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$143
- Janssen Scientific Affairs, LLC$115
- Jazz Pharmaceuticals Inc.$90
- Amgen$47
- Sanofi-aventis U.S. LLC$38
- Syndax Pharmaceuticals, Inc.$27
- plus $40 from 2 others
What the payments were for
- Consulting fees$11523%
- Food & beverage$24348%
- Education$14329%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $143 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| Jazz Pharmaceuticals Inc. | 3 | $90 |
| Amgen | 2 | $47 |
| Sanofi-aventis U.S. LLC | 1 | $38 |
| Syndax Pharmaceuticals, Inc. | 1 | $27 |
| Seagen Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TALVEY$115
How this compares
$501 in reported general payments places this provider in the 55th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Posaconazole | 16 | $20,558 |
| Ursodiol | 13 | $1,184 |
| Tacrolimus | 11 | $1,105 |
| Acyclovir | 31 | $177 |
| Ondansetron Hcl | 15 | $54 |
Paid to pharmacies, not to this prescriber.
Other family in Scottsdale
- Kaitlyn LouchheimScottsdale$208K
- Jennifer PrinceScottsdale$76K
- Camilla BinksScottsdale$62K
- Jessica TapiaScottsdale$36K
- Dawn MougelScottsdale$34K
- Keegan RussellScottsdale$28K
- Jamie HowardScottsdale$14K
- Anna CramerScottsdale$14K
- Sharon MagalonaMesa$441K
- Angela GoldenMunds Park$378K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.